REVIEW: CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application

---

Elizaveta P. Minina¹, Dmitry V. Dianov¹, Saveliy A. Sheetikov¹, and Apollinariya V. Bogolyubova^1,a*

¹National Medical Research Centre for Hematology, Ministry of Health of the Russian Federation, 125167 Moscow, Russia

Received August 14, 2023; Revised November 23, 2023; Accepted December 2, 2023

---

Chimeric antigen receptors (CARs) are genetically engineered receptors that recognize antigens and activate signaling cascades in a cell. Signal recognition and transmission are mediated by the CAR domains derived from different proteins. T cells carrying CARs against tumor-associated antigens have been used in the development of the CAR T cell therapy, a new approach to fighting malignant neoplasms. Despite its high efficacy in the treatment of oncohematological diseases, CAR T cell therapy has a number of disadvantages that could be avoided by using other types of leukocytes as effector cells. CARs can be expressed in a wide range of cells of adaptive and innate immunity with the emergence or improvement of cytotoxic properties. This review discusses the features of CAR function in different types of immune cells, with a particular focus on the results of preclinical and clinical efficacy studies and the safety of potential CAR cell products.

---

KEY WORDS: chimeric antigen receptor, immunotherapy, cell therapy, CAR, CAR T cell, CAR NK cell

DOI: 10.1134/S0006297924050018

Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---